Skip to main content
Erschienen in: AIDS and Behavior 1/2019

03.07.2018 | Original Paper

Fecal Coliform Bacterial Detection to Assess Enema Adherence in HIV Prevention Clinical Studies

verfasst von: Wutyi S. Aung, Rahul P. Bakshi, Jennifer Breakey, James E. Johnson, Craig W. Hendrix, Ethel Weld, Edward J. Fuchs, Mark A. Marzinke

Erschienen in: AIDS and Behavior | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Evaluating the efficacy of any HIV prevention strategy is dependent on ensuring and objectively monitoring adherence to the intervention. Medicated rectal enemas are a potential method for providing topical, episodic HIV prophylaxis during receptive anal intercourse. Assessing adherence to recommended enema dosing regimens is essential in evaluating the utility of this strategy. We utilized fecal coliform bacteria on used enema tips as a marker for enema use. Enema tip coliforms were tested by repurposing a microtiter plate-based water quality test designed to detect fecal contamination of water. Coliform detection occurred with 100% sensitivity and specificity when tips were assayed on day of use. The assay performed well post-7 day sample storage at room temperature, yielding a sensitivity of 80% and specificity of 93%. All (n = 64) samples collected in a subset of the DREAM-01 rectal microbicide enema clinical trial tested positive, even when tips were evaluated > 7 days post-reported use. The coliform-based enema tip assay allows monitoring of adherence in interventions involving rectal enemas in a sensitive, specific and inexpensive manner. The test performs well in clinical trial settings.
Literatur
2.
Zurück zum Zitat Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral
3.
4.
Zurück zum Zitat Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Amico KR, Stirratt MJ. Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis. 2014;59(Suppl 1):S55–60.CrossRefPubMedPubMedCentral Amico KR, Stirratt MJ. Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis. 2014;59(Suppl 1):S55–60.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Williams AB, Amico KR, Bova C, Womack JA. A proposal for quality standards for measuring medication adherence in research. AIDS Behav. 2013;17(1):284–97.CrossRefPubMedPubMedCentral Williams AB, Amico KR, Bova C, Womack JA. A proposal for quality standards for measuring medication adherence in research. AIDS Behav. 2013;17(1):284–97.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Amico KR, Mansoor LE, Corneli A, et al. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav. 2013;17:2143–55.CrossRefPubMedPubMedCentral Amico KR, Mansoor LE, Corneli A, et al. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav. 2013;17:2143–55.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Hendrix CW, Andrade A, Bumpus NN, et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retrovir. 2016;32(1):32–43.CrossRefPubMedPubMedCentral Hendrix CW, Andrade A, Bumpus NN, et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retrovir. 2016;32(1):32–43.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Abaasa A, Hendrix C, Gandhi M, et al. Utility of different adherence measures for PrEP: patterns and incremental value. AIDS Behav. 2018;22(4):1165–73.CrossRefPubMed Abaasa A, Hendrix C, Gandhi M, et al. Utility of different adherence measures for PrEP: patterns and incremental value. AIDS Behav. 2018;22(4):1165–73.CrossRefPubMed
13.
Zurück zum Zitat Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.CrossRefPubMedPubMedCentral Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Podsadecki TJ, Vrijens BC, Tousset EP, et al. “White coat compliance” limits the reliability of therapeutic drug monitoring in HIV-1 infected patients. HIV Clin Trials. 2008;9(4):238–46.CrossRefPubMed Podsadecki TJ, Vrijens BC, Tousset EP, et al. “White coat compliance” limits the reliability of therapeutic drug monitoring in HIV-1 infected patients. HIV Clin Trials. 2008;9(4):238–46.CrossRefPubMed
16.
Zurück zum Zitat Dai JY, Hendrix CW, Richardson BA, et al. Pharmacological measures of treatment adherence and risk of HIV infection in the VOICE study. J Infect Dis. 2016;213(3):335–42.CrossRefPubMed Dai JY, Hendrix CW, Richardson BA, et al. Pharmacological measures of treatment adherence and risk of HIV infection in the VOICE study. J Infect Dis. 2016;213(3):335–42.CrossRefPubMed
18.
Zurück zum Zitat Wallace AR, Teitelbaum A, Wan L, et al. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception. 2007;76(1):53–6.CrossRefPubMed Wallace AR, Teitelbaum A, Wan L, et al. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception. 2007;76(1):53–6.CrossRefPubMed
19.
Zurück zum Zitat Katzen LL, Fernandez-Romero JA, Sarna A, et al. Validation of a dye stain assay for vaginally inserted hydroxyethylcellulose-filled microbicide applicators. Sex Transm Dis. 2011;38(11):1050–5.CrossRefPubMedPubMedCentral Katzen LL, Fernandez-Romero JA, Sarna A, et al. Validation of a dye stain assay for vaginally inserted hydroxyethylcellulose-filled microbicide applicators. Sex Transm Dis. 2011;38(11):1050–5.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Moench TR, O’Hanlon DE, Cone RA. Evaluation of microbicide gel adherence monitoring methods. Sex Transm Dis. 2012;39(5):335–40.CrossRefPubMed Moench TR, O’Hanlon DE, Cone RA. Evaluation of microbicide gel adherence monitoring methods. Sex Transm Dis. 2012;39(5):335–40.CrossRefPubMed
21.
Zurück zum Zitat Hemmerling A, Harrison WG, Brown JM, et al. Trypan blue staining to determine vaginal exposure in two types of plastic vaginal applicators containing two different microbicide formulations. Sex Transm Dis. 2012;39(9):710–2.CrossRefPubMedPubMedCentral Hemmerling A, Harrison WG, Brown JM, et al. Trypan blue staining to determine vaginal exposure in two types of plastic vaginal applicators containing two different microbicide formulations. Sex Transm Dis. 2012;39(9):710–2.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Austin MN, Rabe LK, Hillier SL. Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis. 2009;36(6):368–71.CrossRefPubMedPubMedCentral Austin MN, Rabe LK, Hillier SL. Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis. 2009;36(6):368–71.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121–32.CrossRefPubMedPubMedCentral Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121–32.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Carballo-Diéguez A, Lentz C, Giguere R, et al. Rectal douching associated with receptive anal intercourse: a literature review. AIDS Behav. 2018;22(4):1288–94.CrossRefPubMedPubMedCentral Carballo-Diéguez A, Lentz C, Giguere R, et al. Rectal douching associated with receptive anal intercourse: a literature review. AIDS Behav. 2018;22(4):1288–94.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Weld ED, Fuchs E, Marzinke M, et al. Tenofovir enema as HIV PrEP for receptive anal intercourse: safety, pharmacokinetics, pharmacodynamics and acceptability (DREAM-01) [5647]. Presented at: 9th International AIDS Society Conference on HIV Science; Paris, 2017. Weld ED, Fuchs E, Marzinke M, et al. Tenofovir enema as HIV PrEP for receptive anal intercourse: safety, pharmacokinetics, pharmacodynamics and acceptability (DREAM-01) [5647]. Presented at: 9th International AIDS Society Conference on HIV Science; Paris, 2017.
26.
Zurück zum Zitat Bluewater Biosciences, Inc., ON, Canada. ColiplateTM A quantitative 24-hour test for Coliforms and E. Coli manual. Bluewater Biosciences, Inc., ON, Canada. ColiplateTM A quantitative 24-hour test for Coliforms and E. Coli manual.
28.
Zurück zum Zitat Lifshitz R, Joshi R. Comparison of the novel Coliplate kit and the standard membrane filter technique for enumerating total coliforms and Escherichia coli bacteria in water. Environ Toxicol Water Quality. 1997;13:157–64.CrossRef Lifshitz R, Joshi R. Comparison of the novel Coliplate kit and the standard membrane filter technique for enumerating total coliforms and Escherichia coli bacteria in water. Environ Toxicol Water Quality. 1997;13:157–64.CrossRef
Metadaten
Titel
Fecal Coliform Bacterial Detection to Assess Enema Adherence in HIV Prevention Clinical Studies
verfasst von
Wutyi S. Aung
Rahul P. Bakshi
Jennifer Breakey
James E. Johnson
Craig W. Hendrix
Ethel Weld
Edward J. Fuchs
Mark A. Marzinke
Publikationsdatum
03.07.2018
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 1/2019
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-018-2211-5

Weitere Artikel der Ausgabe 1/2019

AIDS and Behavior 1/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

10.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.